Cargando…

Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report

BACKGROUND: Rebiopsy is highly recommended to identify the mechanism of acquired resistance to EGFR-TKIs in advanced lung cancer. Recent advances in multiplex genotyping based on circulating tumor DNA (ctDNA) provide a strong and non-invasive alternative for detection of the resistance mechanism. CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Wenhua, He, Qihua, Chen, Ying, Chuai, Shaokun, Yin, Weiqiang, Wang, Wei, Peng, Guilin, Zhou, Caicun, He, Jianxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744376/ https://www.ncbi.nlm.nih.gov/pubmed/26850068 http://dx.doi.org/10.1186/s12885-016-2088-5

Ejemplares similares

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
por: Gococo-Benore, Denise A, et al.
Publicado: (2022)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method
por: Maus, Martin K. H., et al.
Publicado: (2012)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
por: Liu, Shaokun, et al.
Publicado: (2020)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
por: Reclusa, Pablo, et al.
Publicado: (2019)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
por: Zeng, Zhu, et al.
Publicado: (2022)

Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung
por: Doval, DC, et al.
Publicado: (2015)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Jin, Guang, et al.
Publicado: (2012)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs
por: Cheon, So Yeong, et al.
Publicado: (2023)

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system
por: Li, Siwen, et al.
Publicado: (2018)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
por: Yang, Hong, et al.
Publicado: (2022)

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer
por: Kim, Young Hun, et al.
Publicado: (2018)

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer
por: Kim, Young Hun, et al.
Publicado: (2019)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
por: Dai, Ying, et al.
Publicado: (2018)

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system: Erratum
por: Li, Siwen, et al.
Publicado: (2020)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma
por: Heriyanto, Didik S., et al.
Publicado: (2020)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ekats8p9doq67t9ibh0o802ioa